Skip to main content

Table 4 Multivariable Cox regression model, including significant variables at the univariate analysis, and survival in bevacizumab-group

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Progression Free Survival (N = 111)

Characteristics

Adjusted HR

95% CI

P

Mucinous histology

No

1

  
 

Yes

2.45

1.19-4.44

0.016

Previous adjuvant CT

No

1

  
 

Yes

1.49

0.84-2.63

0.166

Resected primary tumor

No

1

  
 

Yes

1.59

0.51-3.71

0.383

-1498

C-

1

  
 

T/T

2.28

1.16-4.19

0.018

Overall Survival (N = 111)

Characteristics

Adjusted HR

95% CI

p

Primary tumor

Colon

1

  
 

Rectum

0.40

0.15-1.60

0.245

Mucinous histology

No

1

  
 

Yes

4.22

1.60-9.27

0.009

Leukocytosis

No

1

  
 

Yes

3.02

1.03-10.07

0.043

-1498

C-

1

  
 

T/T

2.22

0.54-5.51

0.195